## Why option 1 is correct Involvement of the subcarinal lymph node station (Station 7), marked **A** in the diagram, represents ipsilateral mediastinal node involvement (N2 disease), which upgrades NSCLC to Stage IIIA. According to Bailey & Love 28e and Harrison 21e, Stage IIIA disease with subcarinal node involvement is generally NOT a candidate for primary surgical resection. The preferred initial approach is concurrent chemoradiation, with surgery reserved for selected cases after neoadjuvant therapy response. This reflects current TNM staging and management guidelines for locally advanced NSCLC. ## Why each distractor is wrong - **Option 2**: Misclassifies the disease as Stage IIB (which would be T3N0 or T1-2N1). Subcarinal node involvement is N2, not N1, and the presence of N2 disease precludes primary surgery as the initial approach. Mediastinal node involvement fundamentally changes the treatment paradigm. - **Option 3**: Confuses N2 (ipsilateral mediastinal) with N3 disease. N3 disease includes contralateral mediastinal/hilar nodes or supraclavicular nodes (Station 1), which would be Stage IIIB and unresectable. Subcarinal involvement alone is N2, not N3. - **Option 4**: While EBUS-TBNA is the procedure of choice for sampling Station 7 (as per Harrison 21e Ch 78), mediastinoscopy has been largely replaced by EBUS-TBNA for accessing subcarinal nodes. This option incorrectly identifies the gold standard diagnostic modality and distracts from the critical staging and management principle. **High-Yield:** Subcarinal (Station 7) node involvement = N2 = Stage IIIA NSCLC → chemoradiation preferred over primary surgery; EBUS-TBNA is the modern gold standard for sampling Station 7. [cite: Bailey & Love 28e; Harrison 21e Ch 78]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.